<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Public Health</journal-id>
<journal-title>Frontiers in Public Health</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Public Health</abbrev-journal-title>
<issn pub-type="epub">2296-2565</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fpubh.2025.1611087</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Public Health</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Videos on YouTube, Bilibili, TikTok as sources of medical information on Hashimoto&#x2019;s thyroiditis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Wang</surname>
<given-names>Shiqi</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="author-notes" rid="fn0003"><sup>&#x2020;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2314373/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Jia</surname>
<given-names>Siyu</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="author-notes" rid="fn0003"><sup>&#x2020;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3034853/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Su</surname>
<given-names>Yanjun</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3229910/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Cheng</surname>
<given-names>Ruochuan</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3107292/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Thyroid Surgery, Clinical Research Center for Thyroid Diseases of Yunnan Province, The First Affiliated Hospital of Kunming Medical University</institution>, <addr-line>Kunming</addr-line>, <country>China</country></aff>
<aff id="aff2"><sup>2</sup><institution>Hend and Neck Tumor Center, Hefei Cancer Hospital, Chinese Academy of Sciences</institution>, <addr-line>Hefei, Anhui</addr-line>, <country>China</country></aff>
<author-notes>
<fn fn-type="edited-by" id="fn0001">
<p>Edited by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2184974/overview">Miodrag Zivkovic</ext-link>, Singidunum University, Serbia</p>
</fn>
<fn fn-type="edited-by" id="fn0002">
<p>Reviewed by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3146492/overview">Viviane Euzebia Santos</ext-link>, Federal University of Rio Grande do Norte, Brazil</p>
<p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3148273/overview">Masahiko Sakaguchi</ext-link>, Kochi University, Japan</p>
</fn>
<corresp id="c001">&#x002A;Correspondence: Yanjun Su, <email>153558468@qq.com</email>; Ruochuan Cheng, <email>301059752@qq.com</email></corresp>
<fn fn-type="equal" id="fn0003"><p><sup>&#x2020;</sup>These authors have contributed equally to this work</p></fn>
</author-notes>
<pub-date pub-type="epub">
<day>15</day>
<month>10</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="collection">
<year>2025</year>
</pub-date>
<volume>13</volume>
<elocation-id>1611087</elocation-id>
<history>
<date date-type="received">
<day>13</day>
<month>04</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>29</day>
<month>09</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2025 Wang, Jia, Su and Cheng.</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Wang, Jia, Su and Cheng</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec id="sec1">
<title>Introduction</title>
<p>Hashimoto&#x2019;s thyroiditis (HT), a common autoimmune thyroid disorder, is widely discussed on video-sharing platforms. However, user-generated content about HT lacks systematic scientific validation. This study evaluates the reliability and quality of HT-related videos on three major social media platforms: YouTube, Bilibili, and TikTok.</p>
</sec>
<sec id="sec2">
<title>Methods</title>
<p>Between December 1, 10, 2024, the top 200 videos meeting the criteria retrieved under default search settings using a newly registered user account were included for each platform. These videos were from 107 YouTube accounts, 56 Bilibili accounts and 90 TikTok accounts. Metrics including video parameters and creator profiles were recorded. Content quality was evaluated using five validated assessment tools: PEMAT (Patient Education Materials Assessment Tool), VIQI (Video Information and Quality Index), GQS (Global Quality Score), mDISCERN (modified DISCERN), and JAMA (Journal of the American Medical Association) standards.</p>
</sec>
<sec id="sec3">
<title>Results</title>
<p>TikTok videos showed the highest audience engagement. YouTube had more team-based accounts (43.9%), while TikTok and Bilibili predominantly featured individual accounts, with TikTok featuring a notably higher proportion of verified individual accounts (86.7%). Solo narration was the most common video style across YouTube (62.5%) and TikTok (70.0%), while in Bilibili, it was the medical scenario. In contrast, YouTube and Bilibili offered a broader range of content, including TV programs, documentaries, and educational courses. The varying emphases of different assessment tools rendered it difficult to determine which platform boasts the highest content quality, but the video quality scores across all platforms are not satisfying. Additionally, we found that content produced by verified creators was of higher quality compared to that of unverified creators, with this trend being particularly evident among individual accounts.</p>
</sec>
<sec id="sec4">
<title>Conclusion</title>
<p>Social media platforms provide partial support for the dissemination of health information about HT, but the overall video quality remains suboptimal. We recommend that professional creators pursue platform certification to enhance the dissemination of high-quality HT-related videos.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Hashimoto&#x2019;s thyroiditis</kwd>
<kwd>hypothyroidism</kwd>
<kwd>social media</kwd>
<kwd>health education</kwd>
<kwd>public health</kwd>
</kwd-group>
<counts>
<fig-count count="3"/>
<table-count count="3"/>
<equation-count count="0"/>
<ref-count count="33"/>
<page-count count="9"/>
<word-count count="5788"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Public Health Education and Promotion</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="sec5">
<title>Introduction</title>
<p>Social media is an important way to share health information, especially through videos (<xref ref-type="bibr" rid="ref1">1</xref>). A large number of studies evaluating the information related to thyroid diseases on social media have been indexed in PubMed, such as hypothyroidism (<xref ref-type="bibr" rid="ref2">2</xref>) and hyperthyroidism (<xref ref-type="bibr" rid="ref3">3</xref>), Grave&#x2019;s disease (<xref ref-type="bibr" rid="ref4">4</xref>, <xref ref-type="bibr" rid="ref5">5</xref>), and thyroid cancer (<xref ref-type="bibr" rid="ref6">6</xref>&#x2013;<xref ref-type="bibr" rid="ref11">11</xref>).</p>
<p>Hashimoto&#x2019;s thyroiditis (HT), alternatively referred to as chronic lymphocytic thyroiditis, autoimmune thyroiditis or Hashimoto&#x2019;s disease, represents a thyroid-specific autoimmune disorder defined by three principal pathological features: thyroid gland enlargement, lymphocytic infiltration within thyroid parenchyma, and detectable serum antibodies targeting thyroid-specific antigens. Although the incidence of HT has decreased in recent years, it remains high (216.0 to 161.5 for 2000&#x2013;02 to 2017&#x2013;19; standardized incidence per 100,000 person-years). Across the full study period, the median age at diagnosis for HT was 58&#x2009;years (IQR 43&#x2013;75), indicating an age distribution weighted toward older individuals (<xref ref-type="bibr" rid="ref12">12</xref>). Another epidemiological survey covering 31 major cities in China shows that 10.19% of the total population has positive TPOAb (anti-thyroid peroxidase antibody), and 9.7% has positive TgAb (anti-thyroglobulin antibody) (<xref ref-type="bibr" rid="ref13">13</xref>), both of which are markers of autoimmune thyroid disease. As the most prevalent autoimmune thyroid disorder, HT represents the primary driver of hypothyroidism in regions with sufficient iodine intake (<xref ref-type="bibr" rid="ref14">14</xref>, <xref ref-type="bibr" rid="ref15">15</xref>).</p>
<p>As HT is one of the common causes leading to hypothyroidism, the most relevant research to our study was conducted by Dulak et al. in 2023 (<xref ref-type="bibr" rid="ref2">2</xref>). They assessed the quality of 96 hypothyroidism-related videos on YouTube using the DISCERN tool and Video Power Index (VPI) and concluded that the overall quality of YouTube videos regarding hypothyroidism was poor (<xref ref-type="bibr" rid="ref2">2</xref>). However, this study focused on a single platform, comparative analyses across multiple platforms are still limited, and only one scale was used to evaluate the video quality.</p>
<p>This study offers the first comprehensive analysis of HT-related videos on three large video platforms, YouTube, Bilibili, and TikTok. We thoroughly examine key characteristics and evaluate the content quality of these videos to promote the development of public health education.</p>
</sec>
<sec sec-type="materials|methods" id="sec6">
<title>Materials and methods</title>
<sec id="sec7">
<title>Search strategy</title>
<p><xref ref-type="fig" rid="fig1">Figure 1</xref> outlines the search protocol. Briefly, we conducted video searches on three platforms on October 1, 2024. The English keywords are &#x201C;Hashimoto&#x2019;s thyroiditis&#x201D; and &#x201C;Hashimoto&#x2019;s disease,&#x201D; and the corresponding Chinese keywords are &#x201C;&#x6865;&#x672C;&#x7532;&#x72B6;&#x817A;&#x708E;&#x201D; and &#x201C;&#x6865;&#x672C;&#x75C5;.&#x201D; On YouTube, searches were performed using both English and Chinese keywords concurrently. In contrast, on Bilibili and TikTok, only Chinese keywords were utilized for the search process. To minimize algorithmic bias, we cleared the browser history and used a newly registered account. Videos were reviewed in the default order as determined by the platforms&#x2019; algorithms.</p>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption>
<p>Search strategy for videos on Hashimoto&#x2019;s thyroiditis.</p>
</caption>
<graphic xlink:href="fpubh-13-1611087-g001.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Flowchart comparing YouTube, Bilibili, and TikTok video data for Hashimoto thyroiditis keywords. YouTube starts with 223 videos, excluding 23, resulting in 200 videos from 107 uploaders. Bilibili begins with 278 videos, excluding 78, yielding 200 videos from 56 uploaders. TikTok initiates with 302 videos, excluding 102, resulting in 200 videos from 90 uploaders. Overall, 600 videos progress for further analysis. Finish dates noted are December 1, 2024, and December 2-10, 2024.</alt-text>
</graphic>
</fig>
</sec>
<sec id="sec8">
<title>Data collection</title>
<p>Data collection is divided into two phases. Phase one, lasting 1&#x2009;day, focuses on capturing data that undergoes rapid temporal changes, such as views, likes, coins, collections, shares, and the number of the uploader&#x2019;s followers. These metrics reflected the audience engagement of a video or an account. Phase two, spanning 9&#x2009;days, involves screening out the videos according to the exclusion criteria, collecting time-invariant data (titles, release dates, video lengths, uploader IDs, certification status, uploaders&#x2019; type (individual or team), video topics, video styles), and assessing the video quality. Video styles were categorized into seven types based on the method proposed by Liu et al., including Solo narration, Animation, PPT presentation, etc. (<xref ref-type="bibr" rid="ref16">16</xref>). Video topics were classified into five categories (e.g., Etiology/Prevention; Symptoms; Diagnosis; Treatment/Prognosis; Others), using a study-specific framework developed by the authors. Some videos covered more than one topic. Thus, the number of topics covered by each video was also analyzed. The one that took up the longest duration of the video was defined as the main topic. Detailed information on the methodology is listed in <xref rid="SM1" ref-type="supplementary-material">Supplementary file 1</xref>.</p>
<p>Two evaluators independently assessed and rated video quality using validated measurement tools. Discrepancies in ratings were adjudicated through consultation with a third researcher to establish consensus. These tools were: the Patient Education Materials Assessment Tool (PEMAT), the Video Information Quality Index (VIQI), the Global Quality Scale (GQS), the modified DISCERN instrument (mDISCERN), and the Journal of the American Medical Association (JAMA) benchmark criteria. The complete contents of the tools are documented in <xref rid="SM1" ref-type="supplementary-material">Supplementary files 2, 3</xref>. Video characteristics and uploader characteristics are the secondary outcomes. Video contents and quality assessment are the primary outcomes.</p>
</sec>
<sec id="sec9">
<title>Statistical analysis</title>
<p>Data were analyzed using IBM SPSS 25.0 and GraphPad Prism 8. Data were considered non-normally distributed when the null hypothesis of the Shapiro&#x2013;Wilk test was rejected, and the remaining data were treated as approximately normal for practical purposes. Normally distributed data were expressed as mean&#x00B1;SD and non-normal data as median and 25th&#x2009;~&#x2009;75th percentiles (M [P25&#x2009;~&#x2009;P75]). The Mann&#x2013;Whitney test compared non-parametric variables between two groups, and the Kruskal-Wallis Test for three groups with the Dunn Test for multiple comparisons. As this was an exploratory analysis with no pre-specified primary outcomes, multiple comparison corrections were not applied. A nominal <italic>p</italic>-value &#x003C; 0.05 was considered to suggest a potential signal. Categorical variables were presented as counts and percentages (n (%)) and analyzed through the Chi-square test with the Bonferroni method for multiple comparisons. We used weighed <italic>&#x03BA;</italic> and ICC (Intraclass Correlation Coefficient) to quantify the agreement between the two raters (more details see in <xref rid="SM1" ref-type="supplementary-material">Supplementary file 2</xref>). However, due to the limitations of this study as described in the discussion, a statistically significant difference might not be detected, but did not confirm the absence of a difference.</p>
</sec>
</sec>
<sec sec-type="results" id="sec10">
<title>Results</title>
<sec id="sec11">
<title>Video characteristics</title>
<p>After applying the inclusion and exclusion criteria, the top 200 videos retrieved under default search settings using a newly registered user account were included for each platform, because users typically scroll through approximately 100&#x2009;~&#x2009;200 recommended videos for a given keyword (<xref ref-type="bibr" rid="ref17">17</xref>, <xref ref-type="bibr" rid="ref18">18</xref>). Statistical testing confirmed that all continuous variables exhibited non-normal distributions (Shapiro&#x2013;Wilk test, <italic>p</italic>-value &#x003C; 0.05). YouTube videos demonstrated the longest durations. Due to the restrictions of each platform, some data were not available. TikTok achieved the highest levels of user engagement, as indicated by likes, comments, collections, and shares. Interestingly, despite YouTube having a higher amount of views, thumbs up and comments compared to Bilibili, the ratio of comments to views was lower than that of Bilibili (<xref ref-type="table" rid="tab1">Table 1</xref>).</p>
<table-wrap position="float" id="tab1">
<label>Table 1</label>
<caption>
<p>Characteristics of videos related to Hashimoto&#x2019;s disease on YouTube, Bilibili, and TikTok.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" rowspan="2" valign="top">Platforms</th>
<th align="center" rowspan="2" valign="top">YouTube (N<sub>1</sub>&#x2009;=&#x2009;200)</th>
<th align="center" rowspan="2" valign="top">Bilibili (N<sub>2</sub>&#x2009;=&#x2009;200)</th>
<th align="center" rowspan="2" valign="top">TikTok (N<sub>3</sub>&#x2009;=&#x2009;200)</th>
<th align="center" colspan="3" valign="top"><italic>p</italic>-value</th>
</tr>
<tr>
<th align="center" valign="top">P<sub>Y-B</sub></th>
<th align="center" valign="top">P<sub>B-T</sub></th>
<th align="center" valign="top">P<sub>Y-T</sub></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">Video length (seconds)</td>
<td align="center" valign="middle" style="background-color:#fadbdf">243 [110&#x2009;~&#x2009;603]</td>
<td align="center" valign="middle">152 [98&#x2009;~&#x2009;262]</td>
<td align="center" valign="middle" style="background-color:#fef2cb">80 [54&#x2009;~&#x2009;130]</td>
<td align="center" valign="middle"><bold>0.003</bold></td>
<td align="center" valign="middle"><bold>&#x003C;0.001</bold></td>
<td align="center" valign="middle"><bold>&#x003C;0.001</bold></td>
</tr>
<tr>
<td align="left" valign="middle">Views</td>
<td align="center" valign="middle" style="background-color:#fadbdf">3,894 [158&#x2009;~&#x2009;32,769]</td>
<td align="center" valign="middle">1754 [472&#x2009;~&#x2009;5,238]</td>
<td align="center" valign="middle"><bold>-</bold></td>
<td align="center" valign="middle"><bold>0.008</bold></td>
<td align="center" valign="middle"><bold>-</bold></td>
<td align="center" valign="middle"><bold>-</bold></td>
</tr>
<tr>
<td align="left" valign="middle">Thumbs up</td>
<td align="center" valign="middle">98 [0&#x2009;~&#x2009;714]<sup>*</sup></td>
<td align="center" valign="middle" style="background-color:#fef2cb">22 [6&#x2009;~&#x2009;69]</td>
<td align="center" valign="middle" style="background-color:#fadbdf">495 [164&#x2009;~&#x2009;2014]</td>
<td align="center" valign="middle"><bold>&#x003C;0.001</bold></td>
<td align="center" valign="middle"><bold>&#x003C;0.001</bold></td>
<td align="center" valign="middle"><bold>&#x003C;0.001</bold></td>
</tr>
<tr>
<td align="left" valign="middle">Comments</td>
<td align="center" valign="middle">5 [0&#x2009;~&#x2009;89]<sup>**</sup></td>
<td align="center" valign="middle" style="background-color:#fef2cb">2 [0&#x2009;~&#x2009;13]</td>
<td align="center" valign="middle" style="background-color:#fadbdf">33 [12&#x2009;~&#x2009;180]</td>
<td align="center" valign="middle"><bold>0.009</bold></td>
<td align="center" valign="middle"><bold>&#x003C;0.001</bold></td>
<td align="center" valign="middle"><bold>&#x003C;0.001</bold></td>
</tr>
<tr>
<td align="left" valign="middle">Collections</td>
<td align="center" valign="middle"><bold>-</bold></td>
<td align="center" valign="middle" style="background-color:#fef2cb">20 [6&#x2009;~&#x2009;70]</td>
<td align="center" valign="middle" style="background-color:#fadbdf">276 [55&#x2009;~&#x2009;1,042]</td>
<td align="center" valign="middle"><bold>-</bold></td>
<td align="center" valign="middle"><bold>&#x003C;0.001</bold></td>
<td align="center" valign="middle"><bold>-</bold></td>
</tr>
<tr>
<td align="left" valign="middle">Shares</td>
<td align="center" valign="middle"><bold>-</bold></td>
<td align="center" valign="middle" style="background-color:#fef2cb">11 [2&#x2009;~&#x2009;36]</td>
<td align="center" valign="middle" style="background-color:#fadbdf">154 [37&#x2009;~&#x2009;798]</td>
<td align="center" valign="middle"><bold>-</bold></td>
<td align="center" valign="middle"><bold>&#x003C;0.001</bold></td>
<td align="center" valign="middle"><bold>-</bold></td>
</tr>
<tr>
<td align="left" valign="middle">Coins</td>
<td align="center" valign="middle"><bold>-</bold></td>
<td align="center" valign="middle">2 [0&#x2009;~&#x2009;8]</td>
<td align="center" valign="middle"><bold>-</bold></td>
<td align="center" valign="middle"><bold>-</bold></td>
<td align="center" valign="middle"><bold>-</bold></td>
<td align="center" valign="middle"><bold>-</bold></td>
</tr>
<tr>
<td align="left" valign="middle">Thumbs-up / Views (%)</td>
<td align="center" valign="middle">1.53 [0.00&#x2009;~&#x2009;3.33]<sup>*</sup></td>
<td align="center" valign="middle">1.43 [0.88&#x2009;~&#x2009;2.13]</td>
<td align="center" valign="middle"><bold>-</bold></td>
<td align="center" valign="middle">0.643</td>
<td align="center" valign="middle"><bold>-</bold></td>
<td align="center" valign="middle"><bold>-</bold></td>
</tr>
<tr>
<td align="left" valign="middle">Comments / Views (%)</td>
<td align="center" valign="middle" style="background-color:#fef2cb">0.06 [0.00&#x2009;~&#x2009;0.29]<sup>**</sup></td>
<td align="center" valign="middle" style="background-color:#fadbdf">0.16 [0.00&#x2009;~&#x2009;0.37]</td>
<td align="center" valign="middle"><bold>-</bold></td>
<td align="center" valign="middle"><bold>0.024</bold></td>
<td align="center" valign="middle"><bold>-</bold></td>
<td align="center" valign="middle"><bold>-</bold></td>
</tr>
<tr>
<td align="left" valign="middle">Collections / Views (%)</td>
<td align="center" valign="middle"><bold>-</bold></td>
<td align="center" valign="middle">1.35 [0.93&#x2009;~&#x2009;2.12]</td>
<td align="center" valign="middle"><bold>-</bold></td>
<td align="center" valign="middle"><bold>-</bold></td>
<td align="center" valign="middle"><bold>-</bold></td>
<td align="center" valign="middle"><bold>-</bold></td>
</tr>
<tr>
<td align="left" valign="middle">Shares / Views (%)</td>
<td align="center" valign="middle"><bold>-</bold></td>
<td align="center" valign="middle">0.63 [0.27&#x2009;~&#x2009;1.08]</td>
<td align="center" valign="middle"><bold>-</bold></td>
<td align="center" valign="middle"><bold>-</bold></td>
<td align="center" valign="middle"><bold>-</bold></td>
<td align="center" valign="middle"><bold>-</bold></td>
</tr>
<tr>
<td align="left" valign="middle">Coins / Views (%)</td>
<td align="center" valign="middle"><bold>-</bold></td>
<td align="center" valign="middle">0.08 [0.00&#x2009;~&#x2009;0.26]</td>
<td align="center" valign="middle"><bold>-</bold></td>
<td align="center" valign="middle"><bold>-</bold></td>
<td align="center" valign="middle"><bold>-</bold></td>
<td align="center" valign="middle"><bold>-</bold></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>Data were presented as Median [P25&#x2009;~&#x2009;P75]. Bold text means the <italic>p</italic>-value&#x003C;0.05. &#x201C;-&#x201D; means &#x201C;not available.&#x201D;</p>
<p>Cells are marked pink when the value shows a nominally significant signal of being higher than others (<italic>p</italic>&#x2009;&#x003C;&#x2009;0.05) and yellow when showing a nominally significant signal of being lower (<italic>p</italic>&#x2009;&#x003C;&#x2009;0.05); no color is applied when no nominally significant signal is detected.</p>
<p><italic>p</italic>-values between two groups were obtained from Mann&#x2013;Whitney U test. <italic>p</italic>-values between three groups were obtained Kruskal-Wallis Test, and Dunn Test was used for multiple comparisons. P<sub>Y-B</sub>, YouTube versus Bilibili; P<sub>B-T</sub>, Bilibili versus TikTok; P<sub>Y-T</sub>, YouTube versus TikTok.</p>
<p>* Excluded: 7 videos on YouTube turned off the function of thumbs-up. **Excluded: 5 videos on YouTube turned off the function of comments.</p>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec12">
<title>Uploader characteristics</title>
<p>The videos enrolled in this study were uploaded by 107 accounts on YouTube, 56 on Bilibili, and 90 on TikTok. <xref ref-type="fig" rid="fig2">Figure 2A</xref> shows the heat map of uploader categories across the three platforms. It&#x2019;s interesting to note that 43.9% of YouTube uploaders were team accounts, while nearly most of the uploaders on Bilibili and TikTok were individuals. Notably, TikTok owned the largest ratio of verified individual creators, and all of them were doctors. Bilibili uploaders owned the smallest number of subscribers (1943 [395&#x2009;~&#x2009;8,920]), while YouTube (40,700 [3,120&#x2009;~&#x2009;255,000]) and TikTok (27,000 [5,472&#x2009;~&#x2009;127,750]) uploaders had more (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). The frequency distribution diagram (<xref ref-type="fig" rid="fig2">Figure 2C</xref>) reveals that most uploaders had only one video included in our study. Nevertheless, a few uploaders demonstrated notably high productivity; the highest output was observed from a Bilibili uploader who released 42 videos enrolled in our study.</p>
<fig position="float" id="fig2">
<label>Figure 2</label>
<caption>
<p>Uploader characteristics on YouTube, Bilibili, and TikTok. <bold>(A)</bold> Heat map: Distribution of uploader types per platform (<italic>N</italic>&#x2009;=&#x2009;number of accounts). <bold>(B)</bold> Scatter plot: Number of subscribers. The long vertical line represents the median, and the short vertical line represents the interquartile range. <bold>(C)</bold> The number of videos included in this study for per uploader. &#x002A;<italic>p</italic>-value&#x003C;0.05, &#x002A;&#x002A;<italic>p</italic>-value&#x003C;0.01, &#x002A;&#x002A;&#x002A;<italic>p</italic>-value&#x003C;0.001, &#x002A;&#x002A;&#x002A;&#x002A;<italic>p</italic>-value&#x003C;0.0001, NS, not significant.</p>
</caption>
<graphic xlink:href="fpubh-13-1611087-g002.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Panel A presents a heatmap comparing verified and unverified groups and individuals across YouTube, Bilibili, and TikTok. YouTube has the highest percentage of unverified individuals, while TikTok has the highest percentage of verified individuals. Panel B is a box plot showing subscriber distributions on the three platforms, with TikTok having the highest subscriber count. Panel C is a line chart showing the frequency of uploaded videos, with YouTube showing a broader distribution of video counts compared to Bilibili and TikTok.</alt-text>
</graphic>
</fig>
</sec>
<sec id="sec13">
<title>Video content</title>
<p>In general, the topic of treatment/prognosis was more popular on YouTube and Bilibili than on TikTok, where etiology/prevention dominated the main topics (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Most videos covered 1&#x2009;~&#x2009;2 topics, while 32% YouTube videos, 24.5% TikTok videos, and only 10.5% Bilibili videos covered more than three topics (<xref ref-type="fig" rid="fig3">Figure 3B</xref>).</p>
<fig position="float" id="fig3">
<label>Figure 3</label>
<caption>
<p>Content analysis of videos on YouTube, Bilibili, and TikTok. <bold>(A)</bold> Main topic types. <bold>(B)</bold> Number of topics covered in each video. <bold>(C)</bold> Video style types.</p>
</caption>
<graphic xlink:href="fpubh-13-1611087-g003.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Bar charts labeled A, B, and C compare content categories, topics, and formats across TikTok, Bilibili, and YouTube. Chart A displays categories like symptom, diagnosis, and others. Chart B shows one to six topics. Chart C illustrates formats including solo narration and animation. Counts are shown on the x-axis with color-coded bars representing percentages for each category across the three platforms.</alt-text>
</graphic>
</fig>
<p>As for video production styles, though the solo narration was the predominant format across all platforms, YouTube and Bilibili featured a greater variety of formats, including TV shows/documentaries, animations, and PPT/presentations (<xref ref-type="fig" rid="fig3">Figure 3C</xref>).</p>
</sec>
<sec id="sec14">
<title>Video quality</title>
<p>The agreement between the two evaluators was substantial (<xref rid="SM1" ref-type="supplementary-material">Supplementary file 2</xref>). The varying emphases of different assessment tools rendered it difficult to determine which platform boasts the highest content quality (<xref ref-type="table" rid="tab2">Table 2</xref>).</p>
<table-wrap position="float" id="tab2">
<label>Table 2</label>
<caption>
<p>Quality assessment of videos related to Hashimoto&#x2019;s disease on YouTube/ Bilibili/ TikTok.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Platforms</th>
<th align="center" valign="top">YouTube (<italic>N</italic>&#x2009;=&#x2009;200)</th>
<th align="center" valign="top">Bilibili (<italic>N</italic>&#x2009;=&#x2009;200)</th>
<th align="center" valign="top">TikTok (<italic>N</italic>&#x2009;=&#x2009;200)</th>
<th align="center" valign="top"><italic>p</italic>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">PEMAT</td>
<td align="center" valign="middle">75 [69&#x2009;~&#x2009;77]<sub>a</sub></td>
<td align="center" valign="middle" style="background-color:#fef2cb">73 [64&#x2009;~&#x2009;75]<sub>b</sub></td>
<td align="center" valign="middle" style="background-color:#fadbdf">83 [77&#x2009;~&#x2009;85]<sub>c</sub></td>
<td align="center" valign="middle"><bold>&#x003C;0.001</bold></td>
</tr>
<tr>
<td align="left" valign="middle">VIQI</td>
<td align="center" valign="middle" style="background-color:#fadbdf">11 [10&#x2009;~&#x2009;13]<sub>a</sub></td>
<td align="center" valign="middle" style="background-color:#fef2cb">11 [10&#x2009;~&#x2009;11]<sub>b</sub></td>
<td align="center" valign="middle" style="background-color:#fef2cb">11 [10&#x2009;~&#x2009;12]<sub>b</sub></td>
<td align="center" valign="middle"><bold>&#x003C;0.001</bold></td>
</tr>
<tr>
<td align="left" valign="middle">GQS</td>
<td align="center" valign="middle" style="background-color:#fef2cb">3 [3&#x2009;~&#x2009;3]<sub>a</sub></td>
<td align="center" valign="middle" style="background-color:#fadbdf">3 [3&#x2009;~&#x2009;4]<sub>b</sub></td>
<td align="center" valign="middle">3 [3&#x2009;~&#x2009;4]<sub>c</sub></td>
<td align="center" valign="middle"><bold>&#x003C;0.001</bold></td>
</tr>
<tr>
<td align="left" valign="middle">mDISCERN</td>
<td align="center" valign="middle" style="background-color:#fef2cb">3 [3&#x2009;~&#x2009;3]<sub>a</sub></td>
<td align="center" valign="middle" style="background-color:#fadbdf">3 [3&#x2009;~&#x2009;3]<sub>b</sub></td>
<td align="center" valign="middle" style="background-color:#fadbdf">3 [3&#x2009;~&#x2009;3]<sub>b</sub></td>
<td align="center" valign="middle"><bold>&#x003C;0.001</bold></td>
</tr>
<tr>
<td align="left" valign="middle">JAMA</td>
<td align="center" valign="middle" style="background-color:#fef2cb">1 [1&#x2009;~&#x2009;2]<sub>a</sub></td>
<td align="center" valign="middle" style="background-color:#fadbdf">2 [2&#x2009;~&#x2009;2]<sub>b</sub></td>
<td align="center" valign="middle" style="background-color:#fadbdf">2 [2&#x2009;~&#x2009;2]<sub>b</sub></td>
<td align="center" valign="middle"><bold>&#x003C;0.001</bold></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>Data were presented as Median [P25&#x2009;~&#x2009;P75]. Bold text means the <italic>p</italic>-value&#x003C;0.05.</p>
<p><italic>p</italic>-values were obtained from Kruskal-Wallis Test and Dunn Test was used for multiple comparisons: Each subscript letter denotes a subset of &#x201C;Platform&#x201D; categories whose column proportions do not differ significantly from each other at the 0.05 level.</p>
<p>Pink indicates groups that are significantly higher than at least one other group (<italic>p</italic>&#x2009;&#x003C;&#x2009;0.05, Dunn test), and yellow indicates groups that are significantly lower than at least one other group (<italic>p</italic>&#x2009;&#x003C;&#x2009;0.05, Dunn test). If two cells share the same color, it means that both groups differ significantly from at least one other group, but they are not significantly different from each other.</p>
</table-wrap-foot>
</table-wrap>
<p>However, we found that the video quality significantly varied across different types of uploaders (<xref ref-type="table" rid="tab3">Table 3</xref>). There were 5.3% (32/600) videos with obviously unbalanced or misleading information, which were all from the unverified accounts. For instance, some videos claimed that a high-iodine diet can exacerbate Hashimoto&#x2019;s disease without mentioning that these patients also need appropriate iodine. Some videos over-emphasized the connection between food allergies and Hashimoto&#x2019;s disease, especially gluten-free diet. Videos created by unverified individuals had the lowest quality. In contrast, unverified team accounts showed higher video quality than unverified individual ones. Additionally, verified accounts produced higher-quality videos than unverified ones, and no significant difference was observed in video quality between individual and team verified accounts.</p>
<table-wrap position="float" id="tab3">
<label>Table 3</label>
<caption>
<p>Quality assessment of Hashimoto&#x2019;s disease-related-videos uploaded by different types of authors.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Author types</th>
<th align="center" valign="top">Verified<break/>team<break/>(<italic>N</italic>&#x2009;=&#x2009;17)</th>
<th align="center" valign="top">Unverified<break/>team<break/>(<italic>N</italic>&#x2009;=&#x2009;116)</th>
<th align="center" valign="top">Verified individual<break/>(<italic>N</italic>&#x2009;=&#x2009;312)</th>
<th align="center" valign="top">Unverified individual<break/>(<italic>N</italic>&#x2009;=&#x2009;155)</th>
<th align="center" valign="top"><italic>p</italic>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">PEMAT</td>
<td align="center" valign="middle">75 [71&#x2009;~&#x2009;80]<sub>a,b</sub></td>
<td align="center" valign="middle" style="background-color:#fef2cb">75 [69&#x2009;~&#x2009;77]<sub>a</sub></td>
<td align="center" valign="middle" style="background-color:#fadbdf">77 [73&#x2009;~&#x2009;85]<sub>b</sub></td>
<td align="center" valign="middle" style="background-color:#fef2cb">73 [64&#x2009;~&#x2009;77]<sub>a</sub></td>
<td align="center" valign="middle"><bold>&#x003C;0.001</bold></td>
</tr>
<tr>
<td align="left" valign="middle">VIQI</td>
<td align="center" valign="middle" style="background-color:#fadbdf">12 [11.5&#x2009;~&#x2009;14]<sub>a</sub></td>
<td align="center" valign="middle">11 [10&#x2009;~&#x2009;11]<sub>b,c</sub></td>
<td align="center" valign="middle">11 [10&#x2009;~&#x2009;12]<sub>b</sub></td>
<td align="center" valign="middle" style="background-color:#fef2cb">10 [9&#x2009;~&#x2009;12]<sub>c</sub></td>
<td align="center" valign="middle"><bold>&#x003C;0.001</bold></td>
</tr>
<tr>
<td align="left" valign="middle">GQS</td>
<td align="center" valign="middle">3 [3&#x2009;~&#x2009;4]<sub>a,b</sub></td>
<td align="center" valign="middle" style="background-color:#fef2cb">3 [3&#x2009;~&#x2009;3]<sub>a</sub></td>
<td align="center" valign="middle" style="background-color:#fadbdf">4 [3&#x2009;~&#x2009;4]<sub>b</sub></td>
<td align="center" valign="middle" style="background-color:#fef2cb">3 [3&#x2009;~&#x2009;3]<sub>a</sub></td>
<td align="center" valign="middle"><bold>&#x003C;0.001</bold></td>
</tr>
<tr>
<td align="left" valign="middle">mDISCERN</td>
<td align="center" valign="middle">3 [3&#x2009;~&#x2009;3]<sub>a,b</sub></td>
<td align="center" valign="middle" style="background-color:#fef2cb">3 [3&#x2009;~&#x2009;3]<sub>a</sub></td>
<td align="center" valign="middle" style="background-color:#fadbdf">3 [3&#x2009;~&#x2009;3]<sub>b</sub></td>
<td align="center" valign="middle" style="background-color:#fef2cb">3 [3&#x2009;~&#x2009;3]<sub>a</sub></td>
<td align="center" valign="middle"><bold>&#x003C;0.001</bold></td>
</tr>
<tr>
<td align="left" valign="middle">JAMA</td>
<td align="center" valign="middle" style="background-color:#fadbdf">2 [2&#x2009;~&#x2009;2]<sub>a</sub></td>
<td align="center" valign="middle">2 [1&#x2009;~&#x2009;2]<sub>b</sub></td>
<td align="center" valign="middle" style="background-color:#fadbdf">2 [2&#x2009;~&#x2009;2]<sub>a</sub></td>
<td align="center" valign="middle" style="background-color:#fef2cb">2 [1&#x2009;~&#x2009;2]<sub>c</sub></td>
<td align="center" valign="middle"><bold>&#x003C;0.001</bold></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>Data were presented as Median [P25&#x2009;~&#x2009;P75]. Bold text means the <italic>p</italic>-value&#x003C;0.05.</p>
<p><italic>p</italic>-values were obtained from the Kruskal-Wallis. The Dunn Test was used for multiple comparisons: Each subscript letter denotes a subset of &#x201C;Author types&#x201D; categories whose column proportions do not differ significantly from each other at the 0.05 level.</p>
<p>Pink indicates groups that are significantly higher than at least one other group (<italic>p</italic>&#x2009;&#x003C;&#x2009;0.05, Dunn test), and yellow indicates groups that are significantly lower than at least one other group (<italic>p</italic>&#x2009;&#x003C;&#x2009;0.05, Dunn test). If two cells share the same color, it means that both groups differ significantly from at least one other group, but they are not significantly different from each other.</p>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec sec-type="discussion" id="sec15">
<title>Discussion</title>
<p>The use of social media for public health education has significantly increased, with digital video helping to overcome traditional barriers to information access (<xref ref-type="bibr" rid="ref1">1</xref>). This study examines three video-sharing platforms: YouTube, Bilibili, and TikTok, chosen for their market dominance. YouTube, established in 2005, is the globally leading long-form video platform but remains inaccessible in China (<xref ref-type="bibr" rid="ref19">19</xref>), where Bilibili, founded in 2009 and often referred to as &#x201C;Chinese YouTube,&#x201D; is the dominant platform (<xref ref-type="bibr" rid="ref20">20</xref>). TikTok, launched by ByteDance in 2016, has experienced unprecedented growth in short-form video content and holds the record for the fastest development in digital history (<xref ref-type="bibr" rid="ref21">21</xref>).</p>
<p>Several studies have shown that although social media videos enable easy access to health information, the reliability and scientific accuracy of such content are often questionable, which may contribute to the dissemination of misinformation (<xref ref-type="bibr" rid="ref22">22</xref>, <xref ref-type="bibr" rid="ref23">23</xref>).</p>
<p>To date, no studies have comprehensively evaluated the quality of HT-related videos across major video platforms. This study features broader coverage and larger sample size, including 600 videos from three major video platforms. To minimize subjective bias, five evaluation tools were utilized. Furthermore, this study employs a novel uploader classification method, emphasizing the advantages and necessity of verified accounts in information dissemination. It also offers actionable recommendations for the public seeking reliable health information, video creators, and platform operators.</p>
<sec id="sec16">
<title>Video characteristics</title>
<p>Regarding video characteristics, YouTube&#x2019;s global reach and multilingual support contribute to its higher number of views and likes than that of Bilibili. However, the unique &#x201C;bullet-comment&#x201D; and &#x201C;coin&#x201D; systems of Bilibili may have promoted audience engagement, which can be particularly reflected in the ratio of comments to views. This is also a valuable practice that other platforms can learn from. Meanwhile, short videos are better suited to leveraging people&#x2019;s fragmented time, which has driven the rapid rise of short video platforms exemplified by TikTok. The dissemination capabilities of TikTok have been shown to exceed those of long-video platforms that were established earlier. As demonstrated in our study, the number of likes and comments on TikTok far exceeded those on YouTube and Bilibili. This disparity in traffic among the platforms also explains the difference in the number of subscribers for uploaders on different platforms.</p>
</sec>
<sec id="sec17">
<title>Uploader characteristics</title>
<p>In prior studies, the classification of uploaders was subjective and obscured (<xref ref-type="bibr" rid="ref6">6</xref>, <xref ref-type="bibr" rid="ref17">17</xref>, <xref ref-type="bibr" rid="ref24">24</xref>). For example, a speaker claimed to be a doctor in a video; however, as the account has not been verified by the platform, the authenticity of this claim remains uncertain. Nonetheless, some studies might classify it as a professional account, a classification we argue lacks rigor. Consequently, we adopted a more objective approach to classifying the uploader types based on certification status and whether the account was personal or team-based. We referred to Liu et al.&#x2019;s research which provided a detailed method for identifying verified accounts (<xref ref-type="bibr" rid="ref16">16</xref>). The variations in uploader types across different platforms partially mirror the policy directions each platform adopts for medical content creators. As a global video platform, YouTube has attracted a significant number of team-based accounts. Additionally, the platform tends to prioritize traffic allocation to these accounts, enhancing the visibility of their content in search results. However, YouTube&#x2019;s certification process is notably stringent, particularly for individual medical professionals. This may be attributed to the challenges faced by the platform in verifying the credentials of overseas doctors, leading to a considerable number of personal accounts that self-identify as doctors but lack official certification. In contrast, the certification process on Bilibili and TikTok is relatively simplified. Besides, TikTok stipulates that all doctor accounts must complete the certification and their qualifications need to reach the level of attending physician or above, while Bilibili has more lenient restrictions on the identities of creators.</p>
</sec>
<sec id="sec18">
<title>Video content</title>
<p>Many videos have mentioned that although HT cannot be completely prevented, a good diet and regular sleep can to some extent reduce the probability of getting the disease and delay its progression. Low iodine diet, regular re-examination, drug therapy, and surgical treatment are the main therapeutic approaches for HT.</p>
<p>The differences in the types of uploaders also directly affect the content of the videos. The video styles of solo narration and the recording of medical consultation scenes are easy for doctors to produce, short in length, and spread quickly. This explains the constitution of video styles on TikTok. However, the higher proportion of team accounts on YouTube allows for more diverse production styles, such as TV shows and documentaries et al., which demand detailed planning and editing. The form of long videos has also expanded the variety of content on Bilibili. Additionally, under the condition of respecting the patients&#x2019; privacy and obtaining their consent, it is permitted to film real medical scenes in China. Therefore, there are many videos featuring medical scenarios on Bilibili and TikTok. Furthermore, the treatment plans for HT vary greatly depending on the patient&#x2019;s condition, making it difficult to fully elaborate on them in short videos. As a result, related topics are less discussed on TikTok, while they are more common on long-video platforms.</p>
</sec>
<sec id="sec19">
<title>Video quality</title>
<p>Tools are essential for video assessment. All the tools in this research have been widely applied in evaluating the quality of health-related videos. The PEMAT tool, developed in 2014 by Shoemaker, with 17 questions focusing on understandability and actionability (<xref ref-type="bibr" rid="ref25">25</xref>). Given that long-video platforms hosted some videos aimed at medical professionals, which were less comprehensible and actionable for the general public, short-video platforms achieved higher PEMAT scores. The GQS tool, introduced by Bernard in 2007, is simpler and widely used, assessing both video quality and audience engagement (<xref ref-type="bibr" rid="ref26">26</xref>). However, its simplicity may lead to a subjective bias (<xref ref-type="bibr" rid="ref16">16</xref>). Nagpal&#x2019;s VIQI tool, developed in 2015, stresses the video quality through each image, animation, interview, video captions, and summary (<xref ref-type="bibr" rid="ref27">27</xref>). Thus, YouTube with more video styles and team creators had the highest VIQI scores. The mDISCERN tool was refined by Singh in 2012 to assess the video materials (<xref ref-type="bibr" rid="ref28">28</xref>), focusing on clearness, reliability, impartiality, reference, and uncertainty. Regrettably, references and areas of uncertainty were not normally mentioned in videos across nearly all platforms, which resulted in the videos across all platforms generally underperforming in these two sub-items. In 1997, Silberg et al. proposed principles for evaluating online medical information quality in JAMA (<xref ref-type="bibr" rid="ref29">29</xref>). This tool emphasizes authorship with relevant credentials, references, currency, and conflicts of interest. Therefore, TikTok and Bilibili with relatively higher rates of verified accounts, demonstrated a clear advantage in their scores on JAMA. However, in other disease fields, the video quality scores may vary on different platforms. YouTube videos on laryngeal cancer (<xref ref-type="bibr" rid="ref16">16</xref>) and probiotics (<xref ref-type="bibr" rid="ref30">30</xref>) generally scored higher than those on Bilibili, contrasting with Wang&#x2019;s findings on gastric cancer (<xref ref-type="bibr" rid="ref18">18</xref>).</p>
<p>We found that videos produced by verified content creators, predominantly medical professionals, were generally of higher quality. This finding is in accordance with the conclusions of several previous studies, which have demonstrated that the majority of misleading information is disseminated by non-professionals (<xref ref-type="bibr" rid="ref16">16</xref>, <xref ref-type="bibr" rid="ref17">17</xref>, <xref ref-type="bibr" rid="ref31">31</xref>). Therefore, the following recommendations are thus proposed: For the general public, when seeking HT-related information on social media, one should prioritize viewing videos posted by verified accounts. For video creators, qualified professionals are encouraged to promptly apply for account verification. For the platforms, it is essential to establish reasonable verification policies, actively guide creators toward verification, and provide more traffic support to verified accounts.</p>
<p>Additionally, considering some misinformation about HT, we recommend that professionals to produce some videos to debunk the rumors. As for diet, patients with HT are generally recommended to adopt a low-iodine diet, as excessive iodine intake may exacerbate the autoimmune response and lead to thyroid cell damage, but not without-iodine diet. However, patients can normally consume iodized salt to ensure the iodine requirements of the normal human body. The relationship between food allergies and Hashimoto&#x2019;s thyroiditis has not been fully proved at present (<xref ref-type="bibr" rid="ref32">32</xref>). In recent years, interest in the gluten-free diet has increased due to its potential extraintestinal anti-inflammatory effects. Consequently, many patients with Hashimoto&#x2019;s thyroiditis (HT) begin this diet on their own. However, there is not yet enough evidence to recommend this dietary approach to all patients diagnosed with HT (<xref ref-type="bibr" rid="ref33">33</xref>).</p>
</sec>
<sec id="sec20">
<title>Limitations</title>
<p>This study has several limitations. First, subjective evaluation may still exist, despite using five analytical tools and three trained medical professionals. Second, platform restrictions limited access to certain engagement metrics (e.g., collections/shares on YouTube, views on TikTok, and &#x201C;thumbs-down&#x201D; across platforms). Third, all the platform lacks advanced search functions, which may cause some videos to be overlooked. Fourth, focusing only on English and Chinese content raises concerns about cross-cultural applicability. Finally, as a cross-sectional analysis of evolving social media ecosystems, these findings require longitudinal validation. Dynamic updates to platform algorithms could also lead to non-reproducible results.</p>
</sec>
</sec>
<sec sec-type="conclusions" id="sec21">
<title>Conclusion</title>
<p>Social media platforms such as YouTube, Bilibili, and TikTok can help disseminate knowledge about HT to some extent. However, the overall video quality on these platforms requires improvement. The public should prioritize viewing videos from verified accounts. Qualified professionals are encouraged to apply for verification promptly and produce high-quality HT-related videos. Reasonable certification and traffic-support policies can help deliver more high-quality videos to the audience.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="sec22">
<title>Data availability statement</title>
<p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p>
</sec>
<sec sec-type="ethics-statement" id="sec23">
<title>Ethics statement</title>
<p>Ethical approval was not required for the study not involving human data in accordance with the local legislation and institutional requirements. Written informed consent was not required, for either participation in the study or for the publication of potentially/indirectly identifying information, in accordance with the local legislation and institutional requirements. The social media data was accessed and analyzed in accordance with the platform's terms of use and all relevant institutional/national regulations.</p>
</sec>
<sec sec-type="author-contributions" id="sec24">
<title>Author contributions</title>
<p>SW: Writing &#x2013; original draft, Data curation, Methodology. SJ: Data curation, Methodology, Writing &#x2013; review &#x0026; editing. YS: Formal analysis, Writing &#x2013; review &#x0026; editing. RC: Conceptualization, Data curation, Supervision, Writing &#x2013; review &#x0026; editing.</p>
</sec>
<sec sec-type="funding-information" id="sec25">
<title>Funding</title>
<p>The author(s) declare that financial support was received for the research and/or publication of this article. The study was supported by the National Natural Science Foundation of China (Grant No. 82160462), Yunnan Provincial Science and Technology Department (Grant No. 202301AY070001-047), Yunnan Academician and Expert Workstation (No. 202205AF150023), Yunnan Fundamental Research Projects, China (Grant No. 202201AS070068), Xingdian Talents Support Program (Grant No. RLMY20220012), 535 Talent Project of First Affiliated Hospital of Kunming Medical University (Grant No. 2023535D07) and Yunnan Clinical Medical Center for Endocrine and Metabolic Disease (No. YWLCYXZXXYS20221005).</p>
</sec>
<ack>
<p>The authors would like to express their gratitude to the video content creators for their contributions to public health.</p>
</ack>
<sec sec-type="COI-statement" id="sec26">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="ai-statement" id="sec27">
<title>Generative AI statement</title>
<p>The authors declare that no Gen AI was used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p>
</sec>
<sec sec-type="disclaimer" id="sec28">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec sec-type="supplementary-material" id="sec29">
<title>Supplementary material</title>
<p>The Supplementary material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fpubh.2025.1611087/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fpubh.2025.1611087/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Data_Sheet_1.docx" id="SM1" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Data_Sheet_2.docx" id="SM2" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Data_Sheet_3.xls" id="SM3" mimetype="application/vnd.ms-excel" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="ref1"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Patrick</surname><given-names>M</given-names></name> <name><surname>Venkatesh</surname><given-names>RD</given-names></name> <name><surname>Stukus</surname><given-names>DR</given-names></name></person-group>. <article-title>Social media and its impact on health care</article-title>. <source>Ann Allergy Asthma Immunol</source>. (<year>2022</year>) <volume>128</volume>:<fpage>139</fpage>&#x2013;<lpage>45</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.anai.2021.09.014</pub-id>, PMID: <pub-id pub-id-type="pmid">34555532</pub-id></citation></ref>
<ref id="ref2"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dulak</surname><given-names>NA</given-names></name> <name><surname>Anuszkiewicz</surname><given-names>K</given-names></name> <name><surname>Trzcinski</surname><given-names>R</given-names></name> <name><surname>Fanciulli</surname><given-names>G</given-names></name> <name><surname>Stogowski</surname><given-names>P</given-names></name></person-group>. <article-title>Youtube as a patient-information source for hypothyroidism</article-title>. <source>Minerva Endocrinol</source>. (<year>2023</year>) <volume>48</volume>:<fpage>371</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.23736/S2724-6507.22.03732-0</pub-id>, PMID: <pub-id pub-id-type="pmid">35166471</pub-id></citation></ref>
<ref id="ref3"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>San</surname><given-names>H</given-names></name></person-group>. <article-title>Use of youtube as an information source for radioactive iodine therapy: do youtube videos have high quality?</article-title> <source>Mol Imaging Radionucl Ther</source>. (<year>2022</year>) <volume>31</volume>:<fpage>42</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.4274/mirt.galenos.2021.85530</pub-id>, PMID: <pub-id pub-id-type="pmid">35114751</pub-id></citation></ref>
<ref id="ref4"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ilhan</surname><given-names>HD</given-names></name> <name><surname>Cetinkaya Yaprak</surname><given-names>A</given-names></name> <name><surname>Erkan Pota</surname><given-names>C</given-names></name></person-group>. <article-title>Quality analysis of youtube videos about thyroid orbitopathy</article-title>. <source>Int Ophthalmol</source>. (<year>2023</year>) <volume>43</volume>:<fpage>2851</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10792-023-02686-2</pub-id>, PMID: <pub-id pub-id-type="pmid">36930360</pub-id></citation></ref>
<ref id="ref5"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ayo-Ajibola</surname><given-names>O</given-names></name> <name><surname>Davis</surname><given-names>RJ</given-names></name> <name><surname>Theriault</surname><given-names>C</given-names></name> <name><surname>Lamb</surname><given-names>C</given-names></name> <name><surname>Choe</surname><given-names>D</given-names></name> <name><surname>Lin</surname><given-names>ME</given-names></name> <etal/></person-group>. <article-title>Evaluation of youtube as a source for graves' disease information: is high-quality guideline-based information available?</article-title> <source>OTO Open</source>. (<year>2024</year>) <volume>8</volume>:<fpage>e118</fpage>. doi: <pub-id pub-id-type="doi">10.1002/oto2.118</pub-id></citation></ref>
<ref id="ref6"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>S</given-names></name> <name><surname>Zhan</surname><given-names>J</given-names></name> <name><surname>Xu</surname><given-names>X</given-names></name></person-group>. <article-title>Is tiktok a high-quality source of information on thyroid cancer?</article-title> <source>Endocrine</source>. (<year>2023</year>) <volume>81</volume>:<fpage>270</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12020-023-03332-8</pub-id>, PMID: <pub-id pub-id-type="pmid">36840912</pub-id></citation></ref>
<ref id="ref7"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Azer</surname><given-names>SA</given-names></name></person-group>. <article-title>Are discern and jama suitable instruments for assessing youtube videos on thyroid cancer? Methodological concerns</article-title>. <source>J Cancer Educ</source>. (<year>2020</year>) <volume>35</volume>:<fpage>1267</fpage>&#x2013;<lpage>77</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s13187-020-01763-9</pub-id>, PMID: <pub-id pub-id-type="pmid">32472374</pub-id></citation></ref>
<ref id="ref8"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name> <name><surname>Li</surname><given-names>Y</given-names></name> <name><surname>Gu</surname><given-names>J</given-names></name> <name><surname>Xiao</surname><given-names>L</given-names></name></person-group>. <article-title>A quality analysis of thyroid cancer videos available on tiktok</article-title>. <source>Front Public Health</source>. (<year>2023</year>) <volume>11</volume>:<fpage>1049728</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fpubh.2023.1049728</pub-id>, PMID: <pub-id pub-id-type="pmid">37033054</pub-id></citation></ref>
<ref id="ref9"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>E</given-names></name> <name><surname>Ju</surname><given-names>H</given-names></name> <name><surname>Kim</surname><given-names>S</given-names></name> <name><surname>Choi</surname><given-names>J</given-names></name></person-group>. <article-title>Contents analysis of thyroid cancer-related information uploaded to youtube by physicians in Korea: endorsing thyroid cancer screening, potentially leading to overdiagnosis</article-title>. <source>BMC Public Health</source>. (<year>2024</year>) <volume>24</volume>:<fpage>942</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12889-024-18403-2</pub-id>, PMID: <pub-id pub-id-type="pmid">38566004</pub-id></citation></ref>
<ref id="ref10"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aydin</surname><given-names>MA</given-names></name> <name><surname>Akyol</surname><given-names>H</given-names></name></person-group>. <article-title>Quality of information available on youtube videos pertaining to thyroid cancer</article-title>. <source>J Cancer Educ</source>. (<year>2020</year>) <volume>35</volume>:<fpage>599</fpage>&#x2013;<lpage>605</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s13187-019-01502-9</pub-id>, PMID: <pub-id pub-id-type="pmid">30838529</pub-id></citation></ref>
<ref id="ref11"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Samson</surname><given-names>L</given-names></name> <name><surname>Chai</surname><given-names>BS</given-names></name> <name><surname>Ingledew</surname><given-names>P</given-names></name></person-group>. <article-title>Assessment of youtube videos related to radioactive iodine therapy for thyroid cancer for patient education</article-title>. <source>J Cancer Educ</source>. (<year>2024</year>) <volume>40</volume>:<fpage>450</fpage>&#x2013;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s13187-024-02531-9</pub-id></citation></ref>
<ref id="ref12"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Conrad</surname><given-names>N</given-names></name> <name><surname>Misra</surname><given-names>S</given-names></name> <name><surname>Verbakel</surname><given-names>JY</given-names></name> <name><surname>Verbeke</surname><given-names>G</given-names></name> <name><surname>Molenberghs</surname><given-names>G</given-names></name> <name><surname>Taylor</surname><given-names>PN</given-names></name> <etal/></person-group>. <article-title>Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the Uk</article-title>. <source>Lancet</source>. (<year>2023</year>) <volume>401</volume>:<fpage>1878</fpage>&#x2013;<lpage>90</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(23)00457-9</pub-id>, PMID: <pub-id pub-id-type="pmid">37156255</pub-id></citation></ref>
<ref id="ref13"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name> <name><surname>Teng</surname><given-names>D</given-names></name> <name><surname>Ba</surname><given-names>J</given-names></name> <name><surname>Chen</surname><given-names>B</given-names></name> <name><surname>Du</surname><given-names>J</given-names></name> <name><surname>He</surname><given-names>L</given-names></name> <etal/></person-group>. <article-title>Efficacy and safety of long-term universal salt iodization on thyroid disorders: epidemiological evidence from 31 provinces of mainland China</article-title>. <source>Thyroid</source>. (<year>2020</year>) <volume>30</volume>:<fpage>568</fpage>&#x2013;<lpage>79</lpage>. doi: <pub-id pub-id-type="doi">10.1089/thy.2019.0067</pub-id>, PMID: <pub-id pub-id-type="pmid">32075540</pub-id></citation></ref>
<ref id="ref14"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ralli</surname><given-names>M</given-names></name> <name><surname>Angeletti</surname><given-names>D</given-names></name> <name><surname>Fiore</surname><given-names>M</given-names></name> <name><surname>D'Aguanno</surname><given-names>V</given-names></name> <name><surname>Lambiase</surname><given-names>A</given-names></name> <name><surname>Artico</surname><given-names>M</given-names></name> <etal/></person-group>. <article-title>Hashimoto's thyroiditis: an update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation</article-title>. <source>Autoimmun Rev</source>. (<year>2020</year>) <volume>19</volume>:<fpage>102649</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.autrev.2020.102649</pub-id>, PMID: <pub-id pub-id-type="pmid">32805423</pub-id></citation></ref>
<ref id="ref15"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ragusa</surname><given-names>F</given-names></name> <name><surname>Fallahi</surname><given-names>P</given-names></name> <name><surname>Elia</surname><given-names>G</given-names></name> <name><surname>Gonnella</surname><given-names>D</given-names></name> <name><surname>Paparo</surname><given-names>SR</given-names></name> <name><surname>Giusti</surname><given-names>C</given-names></name> <etal/></person-group>. <article-title>Hashimotos' thyroiditis: epidemiology, pathogenesis, clinic and therapy</article-title>. <source>Best Pract Res Clin Endocrinol Metab</source>. (<year>2019</year>) <volume>33</volume>:<fpage>101367</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.beem.2019.101367</pub-id>, PMID: <pub-id pub-id-type="pmid">31812326</pub-id></citation></ref>
<ref id="ref16"><label>16.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name> <name><surname>Chen</surname><given-names>Y</given-names></name> <name><surname>Lin</surname><given-names>Y</given-names></name> <name><surname>Ai</surname><given-names>M</given-names></name> <name><surname>Lian</surname><given-names>D</given-names></name> <name><surname>Zhang</surname><given-names>Y</given-names></name> <etal/></person-group>. <article-title>Youtube/ bilibili/ tiktok videos as sources of medical information on laryngeal carcinoma: cross-sectional content analysis study</article-title>. <source>BMC Public Health</source>. (<year>2024</year>) <volume>24</volume>:<fpage>1594</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12889-024-19077-6</pub-id>, PMID: <pub-id pub-id-type="pmid">38877432</pub-id></citation></ref>
<ref id="ref17"><label>17.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Remvig</surname><given-names>CL</given-names></name> <name><surname>Diers</surname><given-names>CS</given-names></name> <name><surname>Meteran</surname><given-names>H</given-names></name> <name><surname>Thomsen</surname><given-names>SF</given-names></name> <name><surname>Sigsgaard</surname><given-names>T</given-names></name> <name><surname>Hoj</surname><given-names>S</given-names></name> <etal/></person-group>. <article-title>Youtube as a source of (mis)information on allergic rhinitis</article-title>. <source>Ann Allergy Asthma Immunol</source>. (<year>2022</year>) <volume>129</volume>:<fpage>612</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.anai.2022.06.031</pub-id></citation></ref>
<ref id="ref18"><label>18.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name> <name><surname>Yao</surname><given-names>N</given-names></name> <name><surname>Wang</surname><given-names>J</given-names></name> <name><surname>Chen</surname><given-names>W</given-names></name> <name><surname>Ouyang</surname><given-names>Y</given-names></name> <name><surname>Xie</surname><given-names>C</given-names></name></person-group>. <article-title>Bilibili, tiktok, and youtube as sources of information on gastric cancer: assessment and analysis of the content and quality</article-title>. <source>BMC Public Health</source>. (<year>2024</year>) <volume>24</volume>:<fpage>57</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12889-023-17323-x</pub-id>, PMID: <pub-id pub-id-type="pmid">38166928</pub-id></citation></ref>
<ref id="ref19"><label>19.</label><citation citation-type="other"><person-group person-group-type="author"><collab id="coll1">Youtube</collab></person-group>. (<year>2025</year>). Youtube - statistics &#x0026; facts. Available online at: <ext-link xlink:href="https://www.statista.com/topics/2019/youtube/#topicOverview" ext-link-type="uri">https://www.statista.com/topics/2019/youtube/#topicOverview</ext-link> (Accessed March 1, 2025).</citation></ref>
<ref id="ref20"><label>20.</label><citation citation-type="other"><person-group person-group-type="author"><collab id="coll2">Bilibili</collab></person-group>. (<year>2024</year>). Bilibili financial information. Available online at: <ext-link xlink:href="https://ir.bilibili.com/en/financial-information/?tab=quarterly-results#quarterly-results" ext-link-type="uri">https://ir.bilibili.com/en/financial-information/?tab=quarterly-results#quarterly-results</ext-link> (accessed March 1, 2024).</citation></ref>
<ref id="ref21"><label>21.</label><citation citation-type="other"><person-group person-group-type="author"><collab id="coll3">Bytedance</collab></person-group>. (<year>2023</year>). Tiktok transparency center. Available online at: <ext-link xlink:href="http://www.tiktok.com/transparency/en/global-transparency-report-2023-4/" ext-link-type="uri">www.tiktok.com/transparency/en/global-transparency-report-2023-4/</ext-link> (accessed March 1, 2023).</citation></ref>
<ref id="ref22"><label>22.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Loeb</surname><given-names>S</given-names></name> <name><surname>Langford</surname><given-names>AT</given-names></name> <name><surname>Bragg</surname><given-names>MA</given-names></name> <name><surname>Sherman</surname><given-names>R</given-names></name> <name><surname>Chan</surname><given-names>JM</given-names></name></person-group>. <article-title>Cancer misinformation on social media</article-title>. <source>CA Cancer J Clin</source>. (<year>2024</year>) <volume>74</volume>:<fpage>453</fpage>&#x2013;<lpage>64</lpage>. doi: <pub-id pub-id-type="doi">10.3322/caac.21857</pub-id>, PMID: <pub-id pub-id-type="pmid">38896503</pub-id></citation></ref>
<ref id="ref23"><label>23.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>G</given-names></name> <name><surname>Goren</surname><given-names>N</given-names></name> <name><surname>Sounderajah</surname><given-names>V</given-names></name> <name><surname>Desalvo</surname><given-names>K</given-names></name></person-group>. <article-title>Information is a determinant of health</article-title>. <source>Nat Med</source>. (<year>2024</year>) <volume>30</volume>:<fpage>927</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41591-023-02792-9</pub-id>, PMID: <pub-id pub-id-type="pmid">38351186</pub-id></citation></ref>
<ref id="ref24"><label>24.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Devendorf</surname><given-names>A</given-names></name> <name><surname>Bender</surname><given-names>A</given-names></name> <name><surname>Rottenberg</surname><given-names>J</given-names></name></person-group>. <article-title>Depression presentations, stigma, and mental health literacy: a critical review and youtube content analysis</article-title>. <source>Clin Psychol Rev</source>. (<year>2020</year>) <volume>78</volume>:<fpage>101843</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cpr.2020.101843</pub-id>, PMID: <pub-id pub-id-type="pmid">32304914</pub-id></citation></ref>
<ref id="ref25"><label>25.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shoemaker</surname><given-names>SJ</given-names></name> <name><surname>Wolf</surname><given-names>MS</given-names></name> <name><surname>Brach</surname><given-names>C</given-names></name></person-group>. <article-title>Development of the patient education materials assessment tool (pemat): a new measure of understandability and actionability for print and audiovisual patient information</article-title>. <source>Patient Educ Couns</source>. (<year>2014</year>) <volume>96</volume>:<fpage>395</fpage>&#x2013;<lpage>403</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.pec.2014.05.027</pub-id>, PMID: <pub-id pub-id-type="pmid">24973195</pub-id></citation></ref>
<ref id="ref26"><label>26.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bernard</surname><given-names>A</given-names></name> <name><surname>Langille</surname><given-names>M</given-names></name> <name><surname>Hughes</surname><given-names>S</given-names></name> <name><surname>Rose</surname><given-names>C</given-names></name> <name><surname>Leddin</surname><given-names>D</given-names></name> <name><surname>Veldhuyzen</surname><given-names>VZS</given-names></name></person-group>. <article-title>A systematic review of patient inflammatory bowel disease information resources on the world wide web</article-title>. <source>Am J Gastroenterol</source>. (<year>2007</year>) <volume>102</volume>:<fpage>2070</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1572-0241.2007.01325.x</pub-id></citation></ref>
<ref id="ref27"><label>27.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nagpal</surname><given-names>SJ</given-names></name> <name><surname>Karimianpour</surname><given-names>A</given-names></name> <name><surname>Mukhija</surname><given-names>D</given-names></name> <name><surname>Mohan</surname><given-names>D</given-names></name> <name><surname>Brateanu</surname><given-names>A</given-names></name></person-group>. <article-title>Youtube videos as a source of medical information during the ebola hemorrhagic fever epidemic</article-title>. <source>Springerplus</source>. (<year>2015</year>) <volume>4</volume>:<fpage>457</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s40064-015-1251-9</pub-id>, PMID: <pub-id pub-id-type="pmid">26322263</pub-id></citation></ref>
<ref id="ref28"><label>28.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>AG</given-names></name> <name><surname>Singh</surname><given-names>S</given-names></name> <name><surname>Singh</surname><given-names>PP</given-names></name></person-group>. <article-title>Youtube for information on rheumatoid arthritis--a wakeup call?</article-title> <source>J Rheumatol</source>. (<year>2012</year>) <volume>39</volume>:<fpage>899</fpage>&#x2013;<lpage>903</lpage>. doi: <pub-id pub-id-type="doi">10.3899/jrheum.111114</pub-id></citation></ref>
<ref id="ref29"><label>29.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Silberg</surname><given-names>WM</given-names></name> <name><surname>Lundberg</surname><given-names>GD</given-names></name> <name><surname>Musacchio</surname><given-names>RA</given-names></name></person-group>. <article-title>Assessing, controlling, and assuring the quality of medical information on the internet: caveant lector et viewor--let the reader and viewer beware</article-title>. <source>JAMA</source>. (<year>1997</year>) <volume>277</volume>:<fpage>1244</fpage>&#x2013;<lpage>5</lpage>.</citation></ref>
<ref id="ref30"><label>30.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>C</given-names></name> <name><surname>Xu</surname><given-names>J</given-names></name> <name><surname>Xu</surname><given-names>C</given-names></name> <name><surname>Chen</surname><given-names>S</given-names></name> <name><surname>Chen</surname><given-names>J</given-names></name> <name><surname>Xia</surname><given-names>J</given-names></name> <etal/></person-group>. <article-title>Status quo of the public's knowledge of probiotics based on video-sharing platforms</article-title>. <source>BMC Public Health</source>. (<year>2023</year>) <volume>23</volume>:<fpage>574</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12889-023-15456-7</pub-id>, PMID: <pub-id pub-id-type="pmid">36978067</pub-id></citation></ref>
<ref id="ref31"><label>31.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name> <name><surname>Mckee</surname><given-names>M</given-names></name> <name><surname>Torbica</surname><given-names>A</given-names></name> <name><surname>Stuckler</surname><given-names>D</given-names></name></person-group>. <article-title>Systematic literature review on the spread of health-related misinformation on social media</article-title>. <source>Soc Sci Med</source>. (<year>2019</year>) <volume>240</volume>:<fpage>112552</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.socscimed.2019.112552</pub-id>, PMID: <pub-id pub-id-type="pmid">31561111</pub-id></citation></ref>
<ref id="ref32"><label>32.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mocellin</surname><given-names>R</given-names></name> <name><surname>Walterfang</surname><given-names>M</given-names></name> <name><surname>Velakoulis</surname><given-names>D</given-names></name></person-group>. <article-title>Hashimoto's encephalopathy: epidemiology, pathogenesis and management</article-title>. <source>CNS Drugs</source>. (<year>2007</year>) <volume>21</volume>:<fpage>799</fpage>&#x2013;<lpage>811</lpage>. doi: <pub-id pub-id-type="doi">10.2165/00023210-200721100-00002</pub-id>, PMID: <pub-id pub-id-type="pmid">17850170</pub-id></citation></ref>
<ref id="ref33"><label>33.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Szczuko</surname><given-names>M</given-names></name> <name><surname>Kwiatkowska</surname><given-names>L</given-names></name> <name><surname>Szczuko</surname><given-names>U</given-names></name> <name><surname>Rudak</surname><given-names>L</given-names></name> <name><surname>Ryterska</surname><given-names>K</given-names></name> <name><surname>Syrenicz</surname><given-names>A</given-names></name> <etal/></person-group>. <article-title>Dietary gluten-free regimen does not affect the suppression of the inflammatory response in the arachidonic acid cascade in Hashimoto's disease</article-title>. <source>Int J Mol Sci</source>. (<year>2025</year>) <volume>26</volume>:<fpage>26</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms26136507</pub-id>, PMID: <pub-id pub-id-type="pmid">40650283</pub-id></citation></ref>
</ref-list>
</back>
</article>